A Phase 2 interventional study of Nivolumab and brentuximab vedotin in Hodgkin Disease, sponsored by Bristol-Myers Squibb. Completed at 79 sites in 11 countries. Open to participants aged 5 Years to 30 Years. Per ClinicalTrials.gov, last updated 2025-02-10.
Sponsored by Bristol-Myers Squibb · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 52 studies testing nivolumab in Hodgkin Disease — 17 open to participants now, 32 under way, 4 of them phase 3. Nivolumab · Hodgkin Disease.
Among the 52 studies testing nivolumab in Hodgkin Disease, this one is the 21st largest by enrollment, is one of 9 that started in 2017, is one of 33 in phase 2, and was the 9th registered.
1,384 studies on the registry are indexed under Hodgkin Disease; 161 are open to participants now.
Browse Hodgkin Disease studies →17 of the 52 studies testing nivolumab in Hodgkin Disease are open now, in 11 countries. Recruiting first, the newest first:
M.D. Anderson Cancer Center · Sites in United States
Ages 2–21
National Research Center for Hematology, Russia · Sites in Russia
Ages 18–60
National Medical Research Radiological Centre of the Ministry of Health of Russia · Sites in Russia
Ages 18+
University of Washington · Sites in United States
Ages 18+
St. Petersburg State Pavlov Medical University · Sites in Russia
Ages 18–60
By country, each count listing its studies:
Nivolumab: first FDA approval 2014 (OPDIVO), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →
Of the 134 Hodgkin Disease studies recruiting now, 71 (53%) set no upper age limit and 51 (38%) stop at 75 or younger; 46 take children under 18; 10 take healthy volunteers.
This study: 5 Years to 30 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
On this site’s reading of the record, nivolumab is the treatment under test here. Read study by study →
52 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 14 · Phase 2 45 · Phase 3 5
First in 2012; this study’s year is marked. 9 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 72 is above the median of 40 across 1,095 interventional studies indexed under Hodgkin Disease.
Median enrollment 52 across the 52 interventional studies. Of the 18 that completed or were terminated, 11 (61%) have results posted.
This tab as a report to print or save as PDF → With an account.
7 of 52 have an industry lead sponsor. The 10 most frequent:
Bristol-Myers Squibb is the lead sponsor of 1,562 studies on the registry; 119 are open to participants now.
Of its 436 completed or terminated interventional studies of FDA-regulated products, 228 (52%) have results posted.
16 studies in Hodgkin Disease by Bristol-Myers Squibb: none open now, none under way, none of them phase 3. Of 15 finished, 8 (53%) have results posted.
Among the 16 studies in Hodgkin Disease by Bristol-Myers Squibb, this one is the 7th largest by enrollment of the 15 interventional ones that give a count, is one of 2 that started in 2017, is one of 5 in phase 2, and was the 14th registered.
Bristol-Myers Squibb’s Hodgkin Disease studies by the year they started, since 2005.
8 of the studies testing nivolumab in Hodgkin Disease that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03681561Veronika BachanovaNivolumab With Ruxolitinib in Relapsed or Refractory Classical Hodgkin Lymphoma | 2026-11 |
| NCT03033914Memorial Sloan Kettering Cancer CenterA(B)VD Followed by Nivolumab as Frontline Therapy for Higher Risk Patients With Classical Hodgkin Lymphoma (HL) | 2027-01 |
| NCT02940301Ohio State University Comprehensive Cancer CenterIbrutinib and Nivolumab in Treating Patients With Relapsed or Refractory Classical Hodgkin Lymphoma | 2027-02-15 |
| NCT05162976City of Hope Medical CenterCC-486 and Nivolumab for the Treatment of Hodgkin Lymphoma Refractory to PD-1 Therapy or Relapsed | 2027-04-27 |
| NCT05272384National Cancer Institute (NCI)Testing the Combination of Nivolumab and ASTX727 for Relapsed or Refractory B-Cell Lymphoma | 2027-06-28 |
Add all 8 to your calendar (.ics) → With an account.
Among the 52 studies testing nivolumab in Hodgkin Disease, from their registry updates:
Among Bristol-Myers Squibb’s 16 in Hodgkin Disease:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to determine whether nivolumab plus brentuximab vedotin (followed by brentuximab vedotin plus bendamustine in patient with suboptimal response) is safe and effective in treating patients with Hodgkin's lymphoma (cHL). Eligible patients are children, adolescents, and young adults relapsed or refractory to first line.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Other protocol defined inclusion/exclusion criteria apply
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.
Studies often ask for 60 or 70 and above. Your doctor gives the score.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Karnofsky performance status (KPS)
A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.
Studies often ask for 60 or 70 and above. Your doctor gives the score.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
PD-1, PD-L1 and checkpoint inhibitors
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biological: Nivolumab · Biological: brentuximab vedotin
Biological: brentuximab vedotin · Biological: bendamustine
Specified Dose on Specified Days
Also known as: BMS-936558, Opdivo
Specified Dose on Specified Days
Specified Dose on Specified Days
Complete Metabolic Response (CMR) Rate at Any Time Prior to Radiation Therapy by Blinded Independent Centralized Review (BICR) - Cohort 1
The complete metabolic response (CMR) rate is defined as the percent of all response-evaluable participants who, assessed by the BICR, achieved best response of CMR. Complete metabolic response (CMR): * Lymph nodes/extralymphatic sites: Score 1, 2, 3 with/without residual mass on 5-point scale * New lesions: No * Bone marrow: No FDG-avid disease Participants who stopped study treatment early for toxicity without a CMR were evaluable. Confidence interval is based on the Clopper and Pearson method
Time frame: From first dose to complete metabolic response or the completion of six cycles of therapy (up to approximately 18 weeks).
Event-free Survival (EFS) Rate at 3 Years by Blinded Independent Centralized Review (BICR) - Cohort 1
Event Free Survival (EFS) is the time from the first treatment to the earliest occurrence of composite events including: Disease progression (PD), Failure to achieve complete metabolic response (CMR) after 4 cycles of N+Bv and 2 cycles of Bv+B, Secondary malignancy, Death . PD : Lymph Nodes and Lesions: new growth or increase of \>= 50% in size from nadir. New or growing lesions outside the lymph nodes. Spleen: Significant increase in spleen size, either from a previously enlarged state or from normal size. New Lesions: Yes Bone Marrow: New or returning FDG-avid disease CMR: Lymph nodes/extralymphatic sites: Score 1, 2, 3 with/without residual mass on 5-point scale New lesions: No Bone marrow: No FDG-avid disease Participants without an "event" were censored at the last tumor assessment. Those who started subsequent anticancer therapy without a prior "event" were censored at the last tumor assessment prior to or upon starting subsequent therapy. Based on Kaplan-Meier Estimates.
Time frame: At 3 years post first dose of study therapy
Complete Metabolic Response (CMR) Rate at Any Time Prior to High Dose Chemotherapy Followed by Autologous Stem Cell Treatment (HDCT/ASCT) by Blinded Independent Centralized Review (BICR) - Cohort 2
The complete metabolic response (CMR) rate is defined as the percent of all response-evaluable participants who, assessed by the BICR, achieved best response of CMR. Complete metabolic response (CMR): * Lymph nodes/extralymphatic sites: Score 1, 2, 3 with/without residual mass on 5-point scale * New lesions: No * Bone marrow: No FDG-avid disease Participants who came off study treatment early for toxicity without a CMR were evaluable. Confidence interval is based on the Clopper and Pearson method
Time frame: From first dose to complete metabolic response or the completion of six cycles of therapy (up to approximately 18 weeks)
Overall Response Rate (ORR) Following 4 Cycles of Nivolumab + Brentuximab Vedotin Treatment by Blinded Independent Centralized Review (BICR)
Overall response rate (ORR) is defined as the percent of all response-evaluable participants who, assessed by the BICR, achieved a best response of complete metabolic response (CMR) or partial metabolic response (PMR). Complete metabolic response (CMR): * Lymph nodes/extralymphatic sites: Score 1, 2, 3 with/without residual mass on 5-point scale * New lesions: No * Bone marrow: No FDG-avid disease Partial metabolic response (PMR): * Lymph nodes/extralymphatic: Score 4 or 5, reduced uptake from baseline * New lesions: None * Bone marrow: Residual uptake higher than normal, reduced from baseline. Participants who came off early for toxicity without CMR or PMR were evaluable.
Time frame: From first dose to PMR or CMR within 4 cycles of therapy, or the completion of four cycles of therapy (N+Bv x4) (up to approximately 12 weeks).
Progression Free Survival (PFS) Rate at 3 Years by Blinded Independent Centralized Review (BICR)
Progression Free Survival (PFS) is the time from the date of first treatment to the date of first documented disease progression by BICR or death. Progressive Disease (PD): Lymph Nodes and Lesions: new growth or increase of \>= 50% in size from nadir. New or growing lesions outside the lymph nodes. Spleen: Significant increase in spleen size, either from a previously enlarged state or from normal size. New Lesions: Yes Bone Marrow: New or returning FDG-avid disease. Participants who neither progressed nor died were censored at the last adequate tumor assessment. Participants who started subsequent anticancer therapy (that is not part of high dose chemotherapy followed by autologous stem cell transplant (HDCT/ASCT) Consolidation Therapy for R2 Cohort) without a prior reported progression or death were censored at the last tumor assessment prior to initiation of the subsequent anticancer therapy. Based on Kaplan-Meier Estimates.
Time frame: At 3 years post first dose of study therapy
Duration of Response (DOR) by Blinded Independent Centralized Review (BICR)
Duration of response (DOR) is the time from first complete metabolic response or partial metabolic response (CMR or PMR) to event free survival EFS (Cohort 1)/progression free survival PFS (Cohort 2) event. For participants with no event, DOR was censored on the date of last tumor assessment. Participants who started subsequent anticancer therapy (not part of high-dose chemotherapy followed by autologous stem cell transplant HDCT/ASCT) without a prior reported EFS/PFS event were censored at the last tumor assessment prior to initiation of the subsequent therapy. Complete metabolic response (CMR): * Lymph nodes/extralymphatic sites: Score 1, 2, 3 with/without residual mass on 5-point scale * New lesions: No * Bone marrow: No FDG-avid disease Partial metabolic response (PMR): * Lymph nodes/extralymphatic: Score 4 or 5, reduced uptake from baseline * New lesions: None * Bone marrow: Residual uptake higher than normal, reduced from baseline. Based on Kaplan-Meier estimates
Time frame: From first dose until disease progression, start of subsequent anti-cancer therapy, or or death due to any cause (up to approximately 86 months)
Complete Metabolic Response (CMR) Rate at Any Time Prior to Radiation Therapy by Investigator - Cohort 1
The complete metabolic response (CMR) rate is defined as the percent of all response-evaluable participants who, assessed by the investigator, achieved best response of CMR. Complete metabolic response (CMR): * Lymph nodes/extralymphatic sites: Score 1, 2, 3 with/without residual mass on 5-point scale * New lesions: No * Bone marrow: No FDG-avid disease Participants who come off early for toxicity without a CMR were evaluable. Confidence interval is based on the Clopper and Pearson method
Time frame: From first dose to complete metabolic response or the completion of six cycles of therapy (up to approximately 18 weeks).
Event-free Survival (EFS) Rate at 3 Years by Investigator - Cohort 1
Event Free Survival (EFS) is the time from the first treatment to the earliest occurrence of composite events including: Disease progression (PD), Failure to achieve complete metabolic response (CMR) after 4 cycles of N+Bv and 2 cycles of Bv+B, Secondary malignancy, Death . PD : Lymph Nodes and Lesions: new growth or increase of \>= 50% in size from nadir. New or growing lesions outside the lymph nodes. Spleen: Significant increase in spleen size, either from a previously enlarged state or from normal size. New Lesions: Yes Bone Marrow: New or returning FDG-avid disease CMR: Lymph nodes/extralymphatic sites: Score 1, 2, 3 with/without residual mass on 5-point scale New lesions: No Bone marrow: No FDG-avid disease Participants without an "event" were censored at the last tumor assessment. Those who started subsequent anticancer therapy without a prior "event" were censored at the last tumor assessment prior to or upon starting subsequent therapy. Based on Kaplan-Meier Estimates.
Time frame: At 3 years post first dose of study therapy
Complete Metabolic Response (CMR) Rate at Any Time Prior to High Dose Chemotherapy Followed by Autologous Stem Cell Treatment (HDCT/ASCT) by Investigator - Cohort 2
The complete metabolic response (CMR) rate is defined as the percent of all response-evaluable participants who, assessed by the investigator, achieved best response of CMR. Complete metabolic response (CMR): * Lymph nodes/extralymphatic sites: Score 1, 2, 3 with/without residual mass on 5-point scale * New lesions: No * Bone marrow: No FDG-avid disease Participants who came off study treatment early for toxicity without a CMR were evaluable. Confidence interval is based on the Clopper and Pearson method.
Time frame: From first dose to complete metabolic response or the completion of six cycles of therapy (up to approximately 18 weeks)
Overall Response Rate (ORR) Following 4 Cycles of Nivolumab + Brentuximab Vedotin Treatment by Investigator
Overall response rate (ORR) is defined as the percent of all response-evaluable participants who, assessed by the investigator, achieve a best response of complete metabolic response (CMR) or partial metabolic response (PMR). Complete metabolic response (CMR): * Lymph nodes/extralymphatic sites: Score 1, 2, 3 with/without residual mass on 5-point scale * New lesions: No * Bone marrow: No FDG-avid disease Partial metabolic response: * Lymph nodes/extralymphatic: Score 4 or 5, reduced uptake from baseline * New lesions: None * Bone marrow: Residual uptake higher than normal, reduced from baseline Participants who came off early for toxicity without CMR or PMR were evaluable.
Time frame: From first dose to PMR or CMR within 4 cycles of therapy, or the completion of four cycles of therapy (N+Bv x4) (up to approximately 12 weeks).
Progression Free Survival (PFS) Rate at 3 Years by Investigator
Progression Free Survival (PFS) is the time from the date of first treatment to the date of first documented disease progression by investigator or death. Progressive Disease (PD): Lymph Nodes and Lesions: new growth or increase of \>= 50% in size from nadir. New or growing lesions outside the lymph nodes. Spleen: Significant increase in spleen size, either from a previously enlarged state or from normal size. New Lesions: Yes Bone Marrow: New or returning FDG-avid disease. Participants who neither progressed nor died were be censored at the last adequate tumor assessment. Participants who started subsequent anticancer therapy (that is not part of high dose chemotherapy followed by autologous stem cell transplant (HDCT/ASCT) Consolidation Therapy forR2 Cohort) without a prior reported progression or death were censored at the last tumor assessment prior to initiation of the subsequent anticancer therapy. Based on Kaplan-Meier Estimates.
Time frame: At 3 years post first dose
Duration of Response (DOR) by Investigator
Duration of response (DOR) is the time from first complete metabolic response or partial metabolic response (CMR or PMR) to event free survival EFS (Cohort 1)/progression free survival PFS (Cohort 2) event. For participants with no event, the DOR was censored on the date of last tumor assessment. Participants who started subsequent anticancer therapy (not part of high-dose chemotherapy followed by autologous stem cell transplant HDCT/ASCT) without a prior reported EFS/PFS event were censored at the last tumor assessment prior to initiation of the subsequent anticancer therapy. Complete metabolic response (CMR): * Lymph nodes/extralymphatic sites: Score 1, 2, 3 with/without residual mass on 5-point scale * New lesions: No * Bone marrow: No FDG-avid disease Partial metabolic response: * Lymph nodes/extralymphatic: Score 4 or 5, reduced uptake from baseline * New lesions: None * Bone marrow: Residual uptake higher than normal, reduced from baseline. Based on Kaplan-Meier estimates.
Time frame: From first dose until disease progression, start of subsequent anti-cancer therapy, or or death due to any cause (up to approximately 86 months)
The Number of Participants With Adverse Events (AEs)
An Adverse Event (AE) is defined as any new untoward medical occurrence or worsening of a preexisting medical condition in a clinical investigation participant administered study drug and that does not necessarily have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (such as an abnormal laboratory finding), symptom, or disease temporally associated with the use of study drug, whether or not considered related to the study drug.
Time frame: From first dose to 30 days post last dose (an average of 4 months up until a maximum of 7 months).
The Number of Participants With Serious Adverse Events (SAEs)
A Serious Adverse Event (SAE) is defined as any untoward medical occurrence that, at any dose: * Results in death * Is life-threatening (defined as an event in which the participant was at risk of death at the time of the event; it does not refer to an event which hypothetically might have caused death if it were more severe) * Requires inpatient hospitalization or causes prolongation of existing hospitalization * Results in persistent or significant disability/incapacity * Is a congenital anomaly/birth defect * Is an important medical event.
Time frame: From first dose to 30 days post last dose (an average of 4 months up until a maximum of 7 months)
The Number of Participants With Abnormal Laboratory Values for Specific Thyroid Tests
The Number of Participants with Abnormal Laboratory Values for Specific Thyroid Tests.
Time frame: From first dose to 30 days post last dose (an average of 4 months up until a maximum of 7 months)
The Number of Participants With Abnormal Laboratory Values for Liver Tests
The Number of Participants with Abnormal Laboratory Values for Liver Tests.
Time frame: From first dose to 30 days post last dose (an average of 4 months up until a maximum of 7 months)
Number of Participants With Abnormal Vital Signs Reported as Adverse Events
Temperature, blood pressure, and heart rate abnormalities reported as adverse events.
Time frame: From first dose to 100 days after last dose of study therapy (assessed for an average of 7 months up until a maximum of 10 months).
| Milestone | Cohort 1: Relapsed/Refractory Classic Hodgkin Lymphoma - Low Risk Relapse | Cohort 2: Relapsed/Refractory Classic Hodgkin Lymphoma - Standard Risk Relapse |
|---|---|---|
| Started | 28 | 44 |
| Completed | 27 | 42 |
| Not completed | 1 | 2 |
| Withdrew: Study drug toxicity | 1 | 1 |
| Withdrew: Disease progression | 0 | 1 |
| Milestone | Cohort 1: Relapsed/Refractory Classic Hodgkin Lymphoma - Low Risk Relapse | Cohort 2: Relapsed/Refractory Classic Hodgkin Lymphoma - Standard Risk Relapse |
|---|---|---|
| Started | 22 | 32 |
| Completed | 22 | 32 |
| Not completed | 0 | 0 |
| Milestone | Cohort 1: Relapsed/Refractory Classic Hodgkin Lymphoma - Low Risk Relapse | Cohort 2: Relapsed/Refractory Classic Hodgkin Lymphoma - Standard Risk Relapse |
|---|---|---|
| Started | 6 | 11 |
| Completed | 5 | 11 |
| Not completed | 1 | 0 |
| Withdrew: Study drug toxicity | 1 | 0 |
The complete metabolic response (CMR) rate is defined as the percent of all response-evaluable participants who, assessed by the BICR, achieved best response of CMR. Complete metabolic response (CMR): * Lymph nodes/extralymphatic sites: Score 1, 2, 3 with/without residual mass on 5-point scale * New lesions: No * Bone marrow: No FDG-avid disease Participants who stopped study treatment early for toxicity without a CMR were evaluable. Confidence interval is based on the Clopper and Pearson method
| Percent of participants | Cohort 1: Relapsed/Refractory Classic Hodgkin Lymphoma - Low Risk Relapse |
|---|---|
| Complete Metabolic Response (CMR) Rate at Any Time Prior to Radiation Therapy by Blinded Independent Centralized Review (BICR) - Cohort 1 | 92.9 (79.2 to 98.7) |
Event Free Survival (EFS) is the time from the first treatment to the earliest occurrence of composite events including: Disease progression (PD), Failure to achieve complete metabolic response (CMR) after 4 cycles of N+Bv and 2 cycles of Bv+B, Secondary malignancy, Death . PD : Lymph Nodes and Lesions: new growth or increase of \>= 50% in size from nadir. New or growing lesions outside the lymph nodes. Spleen: Significant increase in spleen size, either from a previously enlarged state or from normal size. New Lesions: Yes Bone Marrow: New or returning FDG-avid disease CMR: Lymph nodes/extralymphatic sites: Score 1, 2, 3 with/without residual mass on 5-point scale New lesions: No Bone marrow: No FDG-avid disease Participants without an "event" were censored at the last tumor assessment. Those who started subsequent anticancer therapy without a prior "event" were censored at the last tumor assessment prior to or upon starting subsequent therapy. Based on Kaplan-Meier Estimates.
| Percent of participants | Cohort 1: Relapsed/Refractory Classic Hodgkin Lymphoma - Low Risk Relapse |
|---|---|
| Event-free Survival (EFS) Rate at 3 Years by Blinded Independent Centralized Review (BICR) - Cohort 1 | 87.5 (70.6 to 95.0) |
The complete metabolic response (CMR) rate is defined as the percent of all response-evaluable participants who, assessed by the BICR, achieved best response of CMR. Complete metabolic response (CMR): * Lymph nodes/extralymphatic sites: Score 1, 2, 3 with/without residual mass on 5-point scale * New lesions: No * Bone marrow: No FDG-avid disease Participants who came off study treatment early for toxicity without a CMR were evaluable. Confidence interval is based on the Clopper and Pearson method
| Percent of participants | Cohort 2: Relapsed/Refractory Classic Hodgkin Lymphoma - Standard Risk Relapse |
|---|---|
| Complete Metabolic Response (CMR) Rate at Any Time Prior to High Dose Chemotherapy Followed by Autologous Stem Cell Treatment (HDCT/ASCT) by Blinded Independent Centralized Review (BICR) - Cohort 2 | 88.6 (77.6 to 95.4) |
Overall response rate (ORR) is defined as the percent of all response-evaluable participants who, assessed by the BICR, achieved a best response of complete metabolic response (CMR) or partial metabolic response (PMR). Complete metabolic response (CMR): * Lymph nodes/extralymphatic sites: Score 1, 2, 3 with/without residual mass on 5-point scale * New lesions: No * Bone marrow: No FDG-avid disease Partial metabolic response (PMR): * Lymph nodes/extralymphatic: Score 4 or 5, reduced uptake from baseline * New lesions: None * Bone marrow: Residual uptake higher than normal, reduced from baseline. Participants who came off early for toxicity without CMR or PMR were evaluable.
| Percent of participants | Cohort 1: Relapsed/Refractory Classic Hodgkin Lymphoma - Low Risk Relapse | Cohort 2: Relapsed/Refractory Classic Hodgkin Lymphoma - Standard Risk Relapse |
|---|---|---|
| Overall Response Rate (ORR) Following 4 Cycles of Nivolumab + Brentuximab Vedotin Treatment by Blinded Independent Centralized Review (BICR) | 96.4 (84.1 to 99.8) | 93.2 (83.3 to 98.1) |
Progression Free Survival (PFS) is the time from the date of first treatment to the date of first documented disease progression by BICR or death. Progressive Disease (PD): Lymph Nodes and Lesions: new growth or increase of \>= 50% in size from nadir. New or growing lesions outside the lymph nodes. Spleen: Significant increase in spleen size, either from a previously enlarged state or from normal size. New Lesions: Yes Bone Marrow: New or returning FDG-avid disease. Participants who neither progressed nor died were censored at the last adequate tumor assessment. Participants who started subsequent anticancer therapy (that is not part of high dose chemotherapy followed by autologous stem cell transplant (HDCT/ASCT) Consolidation Therapy for R2 Cohort) without a prior reported progression or death were censored at the last tumor assessment prior to initiation of the subsequent anticancer therapy. Based on Kaplan-Meier Estimates.
| Percent of participants | Cohort 1: Relapsed/Refractory Classic Hodgkin Lymphoma - Low Risk Relapse | Cohort 2: Relapsed/Refractory Classic Hodgkin Lymphoma - Standard Risk Relapse |
|---|---|---|
| Progression Free Survival (PFS) Rate at 3 Years by Blinded Independent Centralized Review (BICR) | 95.2 (77.7 to 99.1) | 91.1 (78.4 to 96.5) |
Duration of response (DOR) is the time from first complete metabolic response or partial metabolic response (CMR or PMR) to event free survival EFS (Cohort 1)/progression free survival PFS (Cohort 2) event. For participants with no event, DOR was censored on the date of last tumor assessment. Participants who started subsequent anticancer therapy (not part of high-dose chemotherapy followed by autologous stem cell transplant HDCT/ASCT) without a prior reported EFS/PFS event were censored at the last tumor assessment prior to initiation of the subsequent therapy. Complete metabolic response (CMR): * Lymph nodes/extralymphatic sites: Score 1, 2, 3 with/without residual mass on 5-point scale * New lesions: No * Bone marrow: No FDG-avid disease Partial metabolic response (PMR): * Lymph nodes/extralymphatic: Score 4 or 5, reduced uptake from baseline * New lesions: None * Bone marrow: Residual uptake higher than normal, reduced from baseline. Based on Kaplan-Meier estimates
| Months | Cohort 1: Relapsed/Refractory Classic Hodgkin Lymphoma - Low Risk Relapse | Cohort 2: Relapsed/Refractory Classic Hodgkin Lymphoma - Standard Risk Relapse |
|---|---|---|
| Duration of Response (DOR) by Blinded Independent Centralized Review (BICR) | NA (NA to NA) | NA (NA to NA) |
The complete metabolic response (CMR) rate is defined as the percent of all response-evaluable participants who, assessed by the investigator, achieved best response of CMR. Complete metabolic response (CMR): * Lymph nodes/extralymphatic sites: Score 1, 2, 3 with/without residual mass on 5-point scale * New lesions: No * Bone marrow: No FDG-avid disease Participants who come off early for toxicity without a CMR were evaluable. Confidence interval is based on the Clopper and Pearson method
| Percent of participants | Cohort 1: Relapsed/Refractory Classic Hodgkin Lymphoma - Low Risk Relapse |
|---|---|
| Complete Metabolic Response (CMR) Rate at Any Time Prior to Radiation Therapy by Investigator - Cohort 1 | 89.3 (74.6 to 97.0) |
Event Free Survival (EFS) is the time from the first treatment to the earliest occurrence of composite events including: Disease progression (PD), Failure to achieve complete metabolic response (CMR) after 4 cycles of N+Bv and 2 cycles of Bv+B, Secondary malignancy, Death . PD : Lymph Nodes and Lesions: new growth or increase of \>= 50% in size from nadir. New or growing lesions outside the lymph nodes. Spleen: Significant increase in spleen size, either from a previously enlarged state or from normal size. New Lesions: Yes Bone Marrow: New or returning FDG-avid disease CMR: Lymph nodes/extralymphatic sites: Score 1, 2, 3 with/without residual mass on 5-point scale New lesions: No Bone marrow: No FDG-avid disease Participants without an "event" were censored at the last tumor assessment. Those who started subsequent anticancer therapy without a prior "event" were censored at the last tumor assessment prior to or upon starting subsequent therapy. Based on Kaplan-Meier Estimates.
| Percent of participants | Cohort 1: Relapsed/Refractory Classic Hodgkin Lymphoma - Low Risk Relapse |
|---|---|
| Event-free Survival (EFS) Rate at 3 Years by Investigator - Cohort 1 | 88.5 (72.8 to 95.4) |
The complete metabolic response (CMR) rate is defined as the percent of all response-evaluable participants who, assessed by the investigator, achieved best response of CMR. Complete metabolic response (CMR): * Lymph nodes/extralymphatic sites: Score 1, 2, 3 with/without residual mass on 5-point scale * New lesions: No * Bone marrow: No FDG-avid disease Participants who came off study treatment early for toxicity without a CMR were evaluable. Confidence interval is based on the Clopper and Pearson method.
| Percent of participants | Cohort 2: Relapsed/Refractory Classic Hodgkin Lymphoma - Standard Risk Relapse |
|---|---|
| Complete Metabolic Response (CMR) Rate at Any Time Prior to High Dose Chemotherapy Followed by Autologous Stem Cell Treatment (HDCT/ASCT) by Investigator - Cohort 2 | 86.4 (74.8 to 93.9) |
Overall response rate (ORR) is defined as the percent of all response-evaluable participants who, assessed by the investigator, achieve a best response of complete metabolic response (CMR) or partial metabolic response (PMR). Complete metabolic response (CMR): * Lymph nodes/extralymphatic sites: Score 1, 2, 3 with/without residual mass on 5-point scale * New lesions: No * Bone marrow: No FDG-avid disease Partial metabolic response: * Lymph nodes/extralymphatic: Score 4 or 5, reduced uptake from baseline * New lesions: None * Bone marrow: Residual uptake higher than normal, reduced from baseline Participants who came off early for toxicity without CMR or PMR were evaluable.
| Percent of participants | Cohort 1: Relapsed/Refractory Classic Hodgkin Lymphoma - Low Risk Relapse | Cohort 2: Relapsed/Refractory Classic Hodgkin Lymphoma - Standard Risk Relapse |
|---|---|---|
| Overall Response Rate (ORR) Following 4 Cycles of Nivolumab + Brentuximab Vedotin Treatment by Investigator | 100.0 (89.9 to 100.0) | 90.9 (80.4 to 96.8) |
Progression Free Survival (PFS) is the time from the date of first treatment to the date of first documented disease progression by investigator or death. Progressive Disease (PD): Lymph Nodes and Lesions: new growth or increase of \>= 50% in size from nadir. New or growing lesions outside the lymph nodes. Spleen: Significant increase in spleen size, either from a previously enlarged state or from normal size. New Lesions: Yes Bone Marrow: New or returning FDG-avid disease. Participants who neither progressed nor died were be censored at the last adequate tumor assessment. Participants who started subsequent anticancer therapy (that is not part of high dose chemotherapy followed by autologous stem cell transplant (HDCT/ASCT) Consolidation Therapy forR2 Cohort) without a prior reported progression or death were censored at the last tumor assessment prior to initiation of the subsequent anticancer therapy. Based on Kaplan-Meier Estimates.
| Percent of participants | Cohort 1: Relapsed/Refractory Classic Hodgkin Lymphoma - Low Risk Relapse | Cohort 2: Relapsed/Refractory Classic Hodgkin Lymphoma - Standard Risk Relapse |
|---|---|---|
| Progression Free Survival (PFS) Rate at 3 Years by Investigator | 95.8 (80.2 to 99.2) | 88.1 (74.8 to 94.6) |
Duration of response (DOR) is the time from first complete metabolic response or partial metabolic response (CMR or PMR) to event free survival EFS (Cohort 1)/progression free survival PFS (Cohort 2) event. For participants with no event, the DOR was censored on the date of last tumor assessment. Participants who started subsequent anticancer therapy (not part of high-dose chemotherapy followed by autologous stem cell transplant HDCT/ASCT) without a prior reported EFS/PFS event were censored at the last tumor assessment prior to initiation of the subsequent anticancer therapy. Complete metabolic response (CMR): * Lymph nodes/extralymphatic sites: Score 1, 2, 3 with/without residual mass on 5-point scale * New lesions: No * Bone marrow: No FDG-avid disease Partial metabolic response: * Lymph nodes/extralymphatic: Score 4 or 5, reduced uptake from baseline * New lesions: None * Bone marrow: Residual uptake higher than normal, reduced from baseline. Based on Kaplan-Meier estimates.
| Months | Cohort 1: Relapsed/Refractory Classic Hodgkin Lymphoma - Low Risk Relapse | Cohort 2: Relapsed/Refractory Classic Hodgkin Lymphoma - Standard Risk Relapse |
|---|---|---|
| Duration of Response (DOR) by Investigator | NA (NA to NA) | NA (NA to NA) |
An Adverse Event (AE) is defined as any new untoward medical occurrence or worsening of a preexisting medical condition in a clinical investigation participant administered study drug and that does not necessarily have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (such as an abnormal laboratory finding), symptom, or disease temporally associated with the use of study drug, whether or not considered related to the study drug.
| Participants | Cohort 1: Relapsed/Refractory Classic Hodgkin Lymphoma - Low Risk Relapse | Cohort 2: Relapsed/Refractory Classic Hodgkin Lymphoma - Standard Risk Relapse |
|---|---|---|
| The Number of Participants With Adverse Events (AEs) | 26 | 42 |
A Serious Adverse Event (SAE) is defined as any untoward medical occurrence that, at any dose: * Results in death * Is life-threatening (defined as an event in which the participant was at risk of death at the time of the event; it does not refer to an event which hypothetically might have caused death if it were more severe) * Requires inpatient hospitalization or causes prolongation of existing hospitalization * Results in persistent or significant disability/incapacity * Is a congenital anomaly/birth defect * Is an important medical event.
| Participants | Cohort 1: Relapsed/Refractory Classic Hodgkin Lymphoma - Low Risk Relapse | Cohort 2: Relapsed/Refractory Classic Hodgkin Lymphoma - Standard Risk Relapse |
|---|---|---|
| The Number of Participants With Serious Adverse Events (SAEs) | 8 | 9 |
The Number of Participants with Abnormal Laboratory Values for Specific Thyroid Tests.
| Participants | Cohort 1: Relapsed/Refractory Classic Hodgkin Lymphoma - Low Risk Relapse | Cohort 2: Relapsed/Refractory Classic Hodgkin Lymphoma - Standard Risk Relapse |
|---|---|---|
| TSH > ULN | 6 | 8 |
| TSH > ULN WITH TSH <= ULN AT BASELINE | 5 | 4 |
| TSH >ULN WITH ATLEAST ONE FT3/FT4 TEST VALUE <LLN | 1 | 0 |
| TSH >ULN WITH ALL OTHER FT3/FT4 TEST VALUES >= LLN | 4 | 5 |
| TSH > ULN WITH FT3/FT4 TEST MISSING | 1 | 3 |
| TSH < LLN | 4 | 1 |
| TSH <LLN WITH TSH >= LLN AT BASELINE | 4 | 1 |
| TSH <LLN WITH ATLEAST ONE FT3/FT4 TEST VALUE > ULN | 3 | 1 |
| TSH <LLN WITH ALL OTHER FT3/FT4 TEST VALUES <= ULN | 1 | 0 |
| TSH < LLN WITH FT3/FT4 TEST MISSING | 0 | 0 |
The Number of Participants with Abnormal Laboratory Values for Liver Tests.
| Participants | Cohort 1: Relapsed/Refractory Classic Hodgkin Lymphoma - Low Risk Relapse | Cohort 2: Relapsed/Refractory Classic Hodgkin Lymphoma - Standard Risk Relapse |
|---|---|---|
| ALT OR AST > 3XULN | 8 | 5 |
| ALT OR AST> 5XULN | 3 | 1 |
| ALT OR AST> 10XULN | 0 | 0 |
| ALT OR AST > 20XULN | 0 | 0 |
| TOTAL BILIRUBIN > 2XULN | 1 | 0 |
| ALT/AST ELEV>3XULN;TOTAL BILIRUBIN>2XULN IN 1 DAY | 0 | 0 |
| ALT/AST ELEV>3XULN;TOTAL BILIRUBIN>2XULN IN 30 DAYS | 0 | 0 |
Temperature, blood pressure, and heart rate abnormalities reported as adverse events.
| Participants | Cohort 1: Relapsed/Refractory Classic Hodgkin Lymphoma - Low Risk Relapse | Cohort 2: Relapsed/Refractory Classic Hodgkin Lymphoma - Standard Risk Relapse |
|---|---|---|
| Pyrexia | 7 | 23 |
| Tachycardia | 2 | 1 |
| Sinus Bradycardia | 0 | 2 |
| Hypertension | 0 | 4 |
| Hypotension | 0 | 6 |
| Orthostatic hypotension | 0 | 1 |
Collected over Participants were assessed for All-Cause Mortality from first dose until study completion (assessed up to approximately 86 months). SAEs and Other AEs were assessed from first dose to 100 days after last dose of study therapy (assessed for an average of 7 months up until a maximum of 10 months).. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Cohort 1: Relapsed/Refractory Classic Hodgkin Lymphoma - Low Risk Relapse (Nivo + Bv) | 0/22 (0%) | 6/22 (27.3%) | 18/22 (81.8%) |
| Cohort 1: Relapsed/Refractory Classic Hodgkin Lymphoma - Low Risk Relapse (Nivo + Bv) + (Bv + B) | 0/6 (0%) | 3/6 (50%) | 6/6 (100%) |
| Cohort 2: Relapsed/Refractory Classic Hodgkin Lymphoma - Standard Risk Relapse (Nivo + Bv) | 0/33 (0%) | 11/33 (33.3%) | 33/33 (100%) |
| Cohort 2: Relapsed/Refractory Classic Hodgkin Lymphoma - Standard Risk Relapse (Nivo + Bv)+(Bv + B) | 1/11 (9.1%) | 4/11 (36.4%) | 11/11 (100%) |
| Event | Cohort 1: Relapsed/Refractory Classic Hodgkin Lymphoma - Low Risk Relapse (Nivo + Bv) | Cohort 1: Relapsed/Refractory Classic Hodgkin Lymphoma - Low Risk Relapse (Nivo + Bv) + (Bv + B) | Cohort 2: Relapsed/Refractory Classic Hodgkin Lymphoma - Standard Risk Relapse (Nivo + Bv) | Cohort 2: Relapsed/Refractory Classic Hodgkin Lymphoma - Standard Risk Relapse (Nivo + Bv)+(Bv + B) |
|---|---|---|---|---|
| PyrexiaGeneral disorders | 2/22 | 3/6 | 3/33 | 1/11 |
| Otitis mediaInfections and infestations | 0/22 | 1/6 | 0/33 | 0/11 |
| Infusion related reactionInjury, poisoning and procedural complications | 0/22 | 1/6 | 1/33 | 0/11 |
| Pain in extremityMusculoskeletal and connective tissue disorders | 0/22 | 1/6 | 0/33 | 0/11 |
| Acute kidney injuryRenal and urinary disorders | 0/22 | 1/6 | 0/33 | 0/11 |
| UrticariaSkin and subcutaneous tissue disorders | 0/22 | 1/6 | 0/33 | 0/11 |
| StomatitisGastrointestinal disorders | 0/22 | 0/6 | 0/33 | 1/11 |
| Chest painGeneral disorders | 0/22 | 0/6 | 0/33 | 1/11 |
| HypersensitivityImmune system disorders | 1/22 | 0/6 | 1/33 | 1/11 |
| HypoxiaRespiratory, thoracic and mediastinal disorders | 0/22 | 0/6 | 0/33 | 1/11 |
| Event | Cohort 1: Relapsed/Refractory Classic Hodgkin Lymphoma - Low Risk Relapse (Nivo + Bv) | Cohort 1: Relapsed/Refractory Classic Hodgkin Lymphoma - Low Risk Relapse (Nivo + Bv) + (Bv + B) | Cohort 2: Relapsed/Refractory Classic Hodgkin Lymphoma - Standard Risk Relapse (Nivo + Bv) | Cohort 2: Relapsed/Refractory Classic Hodgkin Lymphoma - Standard Risk Relapse (Nivo + Bv)+(Bv + B) |
|---|---|---|---|---|
| NauseaGastrointestinal disorders | 9/22 | 3/6 | 19/33 | 11/11 |
| VomitingGastrointestinal disorders | 2/22 | 3/6 | 7/33 | 6/11 |
| PyrexiaGeneral disorders | 1/22 | 2/6 | 17/33 | 5/11 |
| Mucosal inflammationGeneral disorders | 1/22 | 0/6 | 10/33 | 5/11 |
| Infusion related reactionInjury, poisoning and procedural complications | 4/22 | 1/6 | 4/33 | 5/11 |
| HeadacheNervous system disorders | 10/22 | 2/6 | 6/33 | 4/11 |
| DiarrhoeaGastrointestinal disorders | 5/22 | 1/6 | 13/33 | 4/11 |
| Febrile neutropeniaBlood and lymphatic system disorders | 0/22 | 0/6 | 5/33 | 4/11 |
| Abdominal painGastrointestinal disorders | 1/22 | 0/6 | 9/33 | 4/11 |
| RashSkin and subcutaneous tissue disorders | 0/22 | 0/6 | 3/33 | 4/11 |
| Age, Continuous(Years) | Cohort 1: Relapsed/Refractory Classic Hodgkin Lymphoma - Low Risk Relapse | Cohort 2: Relapsed/Refractory Classic Hodgkin Lymphoma - Standard Risk Relapse | Total |
|---|---|---|---|
| Mean | 17.0 ± 4.3 | 16.2 ± 3.7 | 16.5 ± 4 |
| Sex: Female, Male(Participants) | Cohort 1: Relapsed/Refractory Classic Hodgkin Lymphoma - Low Risk Relapse | Cohort 2: Relapsed/Refractory Classic Hodgkin Lymphoma - Standard Risk Relapse | Total |
|---|---|---|---|
| Female | 18 | 15 | 33 |
| Male | 10 | 29 | 39 |
| Ethnicity (NIH/OMB)(Participants) | Cohort 1: Relapsed/Refractory Classic Hodgkin Lymphoma - Low Risk Relapse | Cohort 2: Relapsed/Refractory Classic Hodgkin Lymphoma - Standard Risk Relapse | Total |
|---|---|---|---|
| Hispanic or Latino | 3 | 1 | 4 |
| Not Hispanic or Latino | 8 | 20 | 28 |
| Unknown or Not Reported | 17 | 23 | 40 |
| Race (NIH/OMB)(Participants) | Cohort 1: Relapsed/Refractory Classic Hodgkin Lymphoma - Low Risk Relapse | Cohort 2: Relapsed/Refractory Classic Hodgkin Lymphoma - Standard Risk Relapse | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 1 | 0 | 1 |
| Native Hawaiian or Other Pacific Islander | 0 | 1 | 1 |
| Black or African American | 1 | 1 | 2 |
| White | 25 | 41 | 66 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 1 | 1 | 2 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Mar 2017 to primary completion in May 2024, 86 months.
Results were first posted in Feb 2025, 8 months after primary completion.
Of 203 phase 2 interventional studies under Hodgkin Disease, half reached primary completion within 75 months of starting (the median), counting those still running; a quarter within 42 and three quarters within 111. This study's 86 months is above that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Nivolumab · Bendamustine